Evidence map›Paper›PMID 42702596›Full record

ArticleNature communications2026

Plasticity of extrachromosomal DNA segregation during drug adaptation.

Chikako Shibata, Kenichi Miyata, Marwa Akao, Kohei Kumegawa, Yumiko Maruyama, Liying Yang, Mana Nagamoto, Ryu-Suke Nozawa, Toru Hirota, Shingo Iwami and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chikako Shibata *Division of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. cshibata-tky@umin.ac.jp.ORCID http://orcid.org/0000-0001-9492-3794
Kenichi Miyata *Division of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8618-3105
Marwa Akaointerdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
Kohei KumegawaCancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3732-2874
Yumiko MaruyamaCenter for Transfusion Medicine and Cell Therapy, Institute of Science Tokyo Hospital, Tokyo, Japan.
Liying YangDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Mana NagamotoDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ryu-Suke NozawaDivision of Experimental Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6609-2436
Toru HirotaDivision of Experimental Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Shingo Iwamiinterdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1780-350X
Shoya Iwanamiinterdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0003-1474-5348
Reo MaruyamaDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. reo.maruyama@jfcr.or.jp.ORCID http://orcid.org/0000-0001-7166-5964

Funding

Japan Agency for Medical Research and Development (AMED) JP24ama221606Japan Agency for Medical Research and Development (AMED) JP26ama221228MEXT | Japan Society for the Promotion of Science (JSPS) JP23K18247MEXT | Japan Society for the Promotion of Science (JSPS) JP23K27446MEXT | Japan Society for the Promotion of Science (JSPS) JP23KJ2162MEXT | Japan Society for the Promotion of Science (JSPS) JP24K02312MEXT | Japan Society for the Promotion of Science (JSPS) JP24K18385MEXT | Japan Society for the Promotion of Science (JSPS) JP25H01036MEXT | Japan Society for the Promotion of Science (JSPS) JP25K22584MEXT | Japan Society for the Promotion of Science (JSPS) JP26K18692
6 · The paper itself

Abstract

Uneven segregation during mitosis is a striking feature of extrachromosomal DNA (ecDNA). Because ecDNA lacks a centromere, it is thought to segregate stochastically, generating intratumoral heterogeneity in genomic copy number. Drug treatment can readily change ecDNA copy number, enabling cells to acquire drug resistance, yet whether these changes reflect static selection of pre-existing clones or active reconfiguration under stress remains unresolved. To address this, we develop a high-throughput framework combining single-cell DNA sequencing with cellular barcoding for clonal tracking. Single-cell cloning reveals that not all clones exhibit identical segregation modes even under drug-free conditions. Under treatment, resistant populations do not simply arise from pre-existing clones with favorable ecDNA states; instead, some clones actively reconfigure their segregation behavior to generate resistant cells. Thus, although ecDNA generally segregates stochastically, it can undergo nonrandom, actively regulated segregation under drug stress, raising the possibility of therapeutically targeting ecDNA segregation mechanisms to counteract adaptive resistance.

Indexed as

Chromosome SegregationDrug Resistance, NeoplasmExtrachromosomal DNACell Line, TumorDNA Copy Number VariationsHumansMitosisSingle-Cell AnalysisExtrachromosomal DNA

Identifiers

PMID42702596
PMCPMC13547322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.